Engineering the Extracellular Matrix
as a Therapeutic Interface
Reprogramming the physical and biological environment of tissues to unlock drug delivery, immune activation, and regenerative outcomes.
At the intersection of oncology, immunology, and regenerative medicine—where formulation meets biology.
The Opportunity
The ECM is not structure—
it is function
The Extracellular Matrix is no longer viewed as passive scaffolding. It is a dynamic, regulatory system that governs critical biological processes — yet most therapeutic strategies continue to treat tissues as uniform environments, ignoring the ECM's complexity.
Drug Penetration & Distribution
Immune Cell Trafficking
Cellular Signalling
Tissue Regeneration & Fibrosis
Platform Vision
From targeting cells to
engineering environments
Our approach shifts the fundamental paradigm of therapeutic intervention — from drug–target interaction to drug–environment interaction. This enables new therapeutic access where conventional approaches fail.
The paradigm shift
Drug–Target Interaction
Drug–Environment Interaction
Modifying ECM structure to enhance delivery penetration and distribution
Leveraging ECM biology to control targeted activation
Using ECM-like systems as sophisticated delivery platforms
R&D Frontiers
Four frontiers of
ECM-directed therapy
Our platform operates across four distinct but interconnected research and development frontiers, each representing a high-value clinical and formulation challenge.
R&D Frontier 01
Remodelling the Tumour
Microenvironment (TME)
Solid tumours develop a dense, fibrotic ECM (desmoplasia) that increases interstitial pressure, restricts drug penetration, and excludes immune cells.
Our Approach
- Decompress tumour architecture for improved perfusion
- Enhance penetration of chemotherapy, immunotherapy, ADCs
- Stabilise fragile biologics (ECM-degrading enzymes)
- Design injectable systems with controlled activity
R&D Frontier 02
Exploiting Matrix
Metalloproteinases (MMPs)
MMPs are endogenous ECM-remodelling enzymes, highly dysregulated in cancer, chronic inflammation, and tissue injury — representing a precision activation lever.
Our Approach
- Engineer MMP-responsive peptide-linked prodrugs
- Develop MMP-sensitive nanocarriers
- Leverage ECM degradation products (matrikines)
R&D Frontier 03
ECM-Derived Drug
Delivery Depots
Rather than breaking down the ECM, we engineer it as a delivery system — enabling localised, sustained, and intelligent drug release.
Our Approach
- Decellularised ECM (dECM)-based systems
- Synthetic ECM-mimicking hydrogels
- Localised injectable depot formulations
R&D Frontier 04
Anti-Fibrotic Therapeutics via
Mechanotransduction
Cells actively sense the mechanical properties of the ECM. When stiffness increases, fibroblasts activate and a pathological feedback loop begins.
Our Approach
- Integrin inhibition (e.g., αvβ6)
- Disruption of stiffness signalling pathways
- Reversal of fibrotic feedback loops
The Core Challenge
The ECM is heterogeneous,
dynamic, and poorly modelled
Traditional pharmacokinetics assumes tissues are uniform. In reality, the ECM varies enormously across tissues, disease states, and individuals.
ECM variables that define drug behaviour
Consequences of ignoring ECM
The SynapTx Advantage
Modelling the physical biology
of drug delivery
SynapTx enables a fundamentally new approach — moving beyond classical pharmacokinetics to model the physical biology of the tissue environment itself.
We model beyond classical PK
SynapTx enables
Platform Advantage
A convergence of biology,
materials science, and formulation
This platform integrates ECM biology, advanced formulation engineering, and predictive modelling through SynapTx — enabling outcomes not possible through any single discipline.
Improved Drug Penetration
Enhanced access through remodelled ECM barriers
Targeted Activation
Disease-environment-driven release and activity
Sustained Local Delivery
Weeks-to-months release from ECM-based depots
Immune & Fibrotic Modulation
Control of immune and fibrotic biological responses
Strategic Positioning
One platform.
Multiple therapeutic frontiers.
This is not a single programme — it is a multi-indication enabling platform spanning four major therapeutic areas.
Oncology
Tumour microenvironment modulation to enhance drug and immune cell penetration
Immunology
Immune activation via ECM signals and matrikine-driven pathway modulation
Regenerative Medicine
Matrix-guided tissue repair and regeneration through ECM-mimicking delivery systems
Fibrotic Diseases
Mechanotransduction targeting across pulmonary, liver, and cardiac fibrosis
Partner With Us
Co-develop the next frontier in
translational pharmacology
We are actively seeking pharmaceutical partners to co-develop ECM-based therapeutic and delivery strategies — from tumour microenvironment modulation to regenerative delivery systems.
Partner or Collaborate With Us